Shilpa Medicare (BOM:530549) Margin of Safety % (DCF Earnings Based): -521.04% (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530549 Shilpa Medicare Ltd BOM:530549
76 GF Score
Price ₹619.55
GF Value ₹387.34
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shilpa Medicare Margin of Safety % (DCF Earnings Based)?

Shilpa Medicare BOM:530549 -2.88% 76 Margin of Safety % (DCF Earnings Based) is -521.04% as of Jul. 18, 2026. GuruFocus rates BOM:530549 with a GF Score™ of 76/100 and a GF Value™ of ₹387.34 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-07-18), Shilpa Medicare's Predictability Rank is 3-Stars. Shilpa Medicare's intrinsic value calculated from the Discounted Earnings model is ₹99.76 and current share price is ₹619.55. Consequently,

Shilpa Medicare's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is -521.04%.

BOM:530549 vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shilpa Medicare Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Shilpa Medicare's Margin of Safety % (DCF Earnings Based) falls into.


BOM:530549
76GF Score
Shilpa Medicare Ltd BOM:530549
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shilpa Medicare Margin of Safety % (DCF Earnings Based) Calculation

Shilpa Medicare's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(99.76-619.55)/99.76
=-521.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

What does a Margin of Safety % (DCF Earnings Based) of -521.04% mean?
Shilpa Medicare (BOM:530549) has a Margin of Safety % (DCF Earnings Based) of -521.04% as of Jul. 18, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Shilpa Medicare.
Is Shilpa Medicare's Margin of Safety % (DCF Earnings Based) too high?
Shilpa Medicare's current Margin of Safety % (DCF Earnings Based) is -521.04%. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Margin of Safety % (DCF Earnings Based) compare to ZTS and UTHR?
Shilpa Medicare's Margin of Safety % (DCF Earnings Based) of -521.04% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Earnings Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Shilpa Medicare. Shilpa Medicare's current Margin of Safety % (DCF Earnings Based) is -521.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (BOM:530549) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.34, compared to a current price of ₹619.55 — trading 59.9% above its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is -521.04%. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Shilpa Medicare (BOM:530549), the current Margin of Safety % (DCF Earnings Based) is -521.04% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shilpa Medicare (BOM:530549) Overvalued in 2026?

Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued. The current stock price of ₹619.55 is trading 59.9% above its estimated GF Value™ of ₹387.34. GuruFocus considers Shilpa Medicare to be Significantly Overvalued.

Key valuation signals for BOM:530549:

  • Margin of Safety % (DCF Earnings Based): -521.04%
  • GF Value™: ₹387.34 vs. price of ₹619.55 (59.9% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the BOM:530549 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shilpa Medicare Business Description

Other Exchanges SHILPAMED:India
Address Hyderabad Road, No. 12-6-214/A-1, Shilpa House, Raichur, KA, IND, 584135
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score

Get the complete analysis for BOM:530549

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹619.55
Price
₹387.34
GF Value